Антитромботическая терапия при фибрилляции предсердий и хронической ишемической болезни сердца

Обзор посвящен применению антитромботической терапии у пациентов с фибрилляцией предсердий (ФП) и хронической ишемической болезнью сердца (ИБС). Обсуждаются данные международных регистров, мета-анализов, оценивающих возможность использования пероральных антикоагулянтов (ПОАК) для вторичной профилактики ИБС. Представлены результаты рандомизированных и наблюдательных клинических исследований, свидетельствующих о преимуществах назначения монотерапии ПОАК при сочетании ФП и хронической ИБС. Представлена современная доказательная база преимущества двухкомпонентной антитромботической терапии с применением прямых ПОАК при проведении чрескожных коронарных вмешательств.  

1. Martin RIR, Bates MGD. Management of atrial fibrillation and concomitant coronary artery disease. Continuing Cardiology Education. 2017;3(2):47–55. DOI: 10.1002/cce2.55

2. Fauchier L, Greenlaw N, Ferrari R, Ford I, Fox KM, Tardif J-C et al. Use of Anticoagulants and Antiplatelet Agents in Stable Outpatients with Coronary Artery Disease and Atrial Fibrillation. International CLARIFY Registry. PLOS ONE. 2015;10(4):e0125164. DOI: 10.1371/journal.pone.0125164

3. Ruff CT, Bhatt DL, Steg PG, Gersh BJ, Alberts MJ, Hoffman EB et al. Long-term cardiovascular outcomes in patients with atrial fibrillation and atherothrombosis in the REACH Registry. International Journal of Cardiology. 2014;170(3):413–8. DOI: 10.1016/j.ijcard.2013.11.030

4. Steinberg BA, Gao H, Shrader P, Pieper K, Thomas L, Camm AJ et al. International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. American Heart Journal. 2017;194:132–40. DOI: 10.1016/j.ahj.2017.08.011

5. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine. 2009;361(12):1139– 51. DOI: 10.1056/NEJMoa0905561

6. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine. 2011;365(10):883–91. DOI: 10.1056/NEJMoa1009638

7. Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M et al. Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine. 2011;365(11):981– 92. DOI: 10.1056/NEJMoa1107039

8. Рычков А. Ю., Хорькова Н. Ю., Минулина А. В. Адекватность антитромботической терапии у пациентов с неклапанной фибрилляцией предсердий в реальной клинической практике. Медицинский совет. 2016;13:85-8

9. Montalescot G, Sechtem W, Achenbach S, Andreotti F, Arden C, Budaj A et al. 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. European Heart Journal. 2013;34(38):2949–3003. DOI: 10.1093/eurheartj/eht296

10. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal. 2016;37(38):2893–962. DOI: 10.1093/eurheartj/ehw210

11. So CH, Eckman MH. Combined aspirin and anticoagulant therapy in patients with atrial fibrillation. Journal of Thrombosis and Thrombolysis. 2017;43(1):7–17. DOI: 10.1007/s11239-016-1425-5

12. Steinberg BA, Kim S, Piccini JP, Fonarow GC, Lopes RD, Thomas L et al. Use and Associated Risks of Concomitant Aspirin Therapy With Oral Anticoagulation in Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. Circulation. 2013;128(7):721– 8. DOI: 10.1161/CIRCULATIONAHA.113.002927

13. Lemesle G, Ducrocq G, Elbez Y, Van Belle E, Goto S, Cannon CP et al. Vitamin K antagonists with or without long-term antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation: Association with ischemic and bleeding events: VKA and APT in patients with stable CAD and AF. Clinical Cardiology. 2017;40(10):932–9. DOI: 10.1002/clc.22750

14. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. European Heart Journal. 2018;39(16):1330–93. DOI: 10.1093/eurheartj/ehy136

15. Anand SS, Yusuf S. Oral anticoagulants in patients with coronary artery disease. Journal of the American College of Cardiology. 2003;41(4 Suppl S):62S-69S. PMID: 12644343

16. Lamberts M, Gislason GH, Lip GYH, Lassen JF, Olesen JB, Mikkelsen AP et al. Antiplatelet Therapy for Stable Coronary Artery Disease in Atrial Fibrillation Patients Taking an Oral Anticoagulant: A Nationwide Cohort Study. Circulation. 2014;129(15):1577–85. DOI: 10.1161/CIRCULATIONAHA.113.004834

17. Hohnloser SH, Oldgren J, Yang S, Wallentin L, Ezekowitz M, Reilly P et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation. 2012;125(5):669–76. DOI: 10.1161/CIRCULATIONAHA.111.055970

18. Сулимов В. А., Голицын С. П., Панченко Е. П., Попов С. В., Ревишвили А. Ш., Шубик Ю. В. и др. Диагностика и лечение фибрилляции пред сердий. Рекомендации РКО, ВНОА и ААСХ. Российский карди ологический журнал. 2013;4(прил. 3):1-100

19. Lee CJ-Y, Gerds TA, Carlson N, Bonde AN, Gislason GH, Lamberts M et al. Risk of Myocardial Infarction in Anticoagulated Patients With Atrial Fibrillation. Journal of the American College of Cardiology. 2018;72(1):17–26. DOI: 10.1016/j.jacc.2018.04.036

20. Turgeon RD, Ackman ML, Babadagli HE, Basaraba JE, Chen JW, Omar M et al. The Role of Direct Oral Anticoagulants in Patients With Coronary Artery Disease. Journal of Cardiovascular Pharmacology and Therapeutics. 2019;24(2):103–12. DOI: 10.1177/1074248418795889

21. APPRAISE Steering Committee and Investigators. Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial. Circulation. 2009;119(22):2877–85. DOI: 10.1161/CIRCULATIONAHA.108.832139

22. Hess CN, James S, Lopes RD, Wojdyla DM, Neely ML, Liaw D et al. Apixaban Plus Mono Versus Dual Antiplatelet Therapy in Acute Coronary Syndromes. Journal of the American College of Cardiology. 2015;66(7):777–87. DOI: 10.1016/j.jacc.2015.06.027

23. Oldgren J, Budaj A, Granger CB, Khder Y, Roberts J, Siegbahn A et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. European Heart Journal. 2011;32(22):2781–9. DOI: 10.1093/eurheartj/ehr113

24. Mega JL, Braunwald E, Wiviott SD, Bassand J-P, Bhatt DL, Bode C et al. Rivaroxaban in patients with a recent acute coronary syndrome. The New England Journal of Medicine. 2012;366(1):9–19. DOI: 10.1056/NEJMoa1112277

25. Mak K-H. Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials. BMJ Open. 2012;2(5):e001592. DOI: 10.1136/bmjopen-2012-001592

26. Valgimigli M, Bueno H, Byrne RA, Collet J-P, Costa F, Jeppsson A et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2018;39(3):213–60. DOI: 10.1093/eurheartj/ehx419

27. Neumann F-J, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal. 2019;40(2):87–165. DOI: 10.1093/eurheartj/ehy394

28. ACTIVE Investigators, Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M et al. Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation. New England Journal of Medicine. 2009;360(20):2066–78. DOI: 10.1056/NEJMoa0901301

29. ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet (London, England). 2006;367(9526):1903–12. DOI: 10.1016/S0140-6736(06)68845-4

30. Camm AJ, Kirchhof P, Lip GYH, Schotten U, Savelieva I, Ernst S et al. Guidelines for the management of atrial fibrillation. EP Europace. 2010;12(10):1360–420. DOI: 10.1093/europace/euq350

31. Li J-X, Li Y, Yan S-J, Han B-H, Song Z-Y, Song W et al. Optimal antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: A systemic review and metaanalysis. Biomedical Reports. 2018;8(2):138–47. DOI: 10.3892/br.2017.1036

32. Dewilde WJM, Oirbans T, Verheugt FWA, Kelder JC, De Smet BJGL, Herrman J-P et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet (London, England). 2013;381(9872):1107–15. DOI: 10.1016/S0140-6736(12)62177-1

33. Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. The New England Journal of Medicine. 2016;375(25):2423–34. DOI: 10.1056/NEJMoa1611594

34. Gibson CM, Pinto DS, Chi G, Arbetter D, Yee M, Mehran R et al. Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy. Circulation. 2017;135(4):323–33. DOI: 10.1161/CIRCULATIONAHA.116.025783

35. Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation – the J-ROCKET AF study –. Circulation Journal: Official Journal of the Japanese Circulation Society. 2012;76(9):2104–11. PMID: 22664783

36. Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. The New England Journal of Medicine. 2017;377(16):1513–24. DOI: 10.1056/NEJMoa1708454

37. Lopes RD, Vora AN, Liaw D, Granger CB, Darius H, Goodman SG et al. An open-Label, 2 . 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial. American Heart Journal. 2018;200:17–23. DOI: 10.1016/j.ahj.2018.03.001

38. Golwala HB, Cannon CP, Steg PG, Doros G, Qamar A, Ellis SG et al. Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials. European Heart Journal. 2018;39(19):1726–1735a. DOI: 10.1093/eurheartj/ehy162

39. Sindet-Pedersen C, Lamberts M, Staerk L, Nissen Bonde A, Berger JS, Pallisgaard JL et al. Combining Oral Anticoagulants With Platelet Inhibitors in Patients With Atrial Fibrillation and Coronary Disease. Journal of the American College of Cardiology. 2018;72(15):1790–800. DOI: 10.1016/j.jacc.2018.07.054